title: Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.
abstract: Much progress in the medical therapy of chronic heart failure (HF) has been made in the last decades. The last was the introduction of a new treatment strategy based on the combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan into the pharmacological armamentarium, as reported in the PARADIGM-HF trial and its ancillary analyses. On the other hand, in the acute setting only scant progress in pharmacological treatments has been achieved, and most published data are based on observational studies or expert opinion. This review critically presents and discusses the most intriguing evidence from clinical trials in HF published in 2015. In particular, we focused on chronic HF with reduced ejection fraction and its comorbidities, while worsening HF or acute decompensated HF were more synthetically treated.
authors.affiliation: a Department of Cardiovascular Research , IRCCS-Istituto di Ricerche Farmacologiche Mario Negri , Milan , Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Latini
authors.affiliation: a Department of Cardiovascular Research , IRCCS-Istituto di Ricerche Farmacologiche Mario Negri , Milan , Italy.
authors.forename: Serge
authors.initials: S
authors.lastname: Masson
authors.affiliation: a Department of Cardiovascular Research , IRCCS-Istituto di Ricerche Farmacologiche Mario Negri , Milan , Italy.
authors.forename: Lidia
authors.initials: L
authors.lastname: Staszewsky
mesh_terms: D000613:Aminobutyrates / Q000494:pharmacology*; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents / Q000494:pharmacology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D054539:Medication Therapy Management / Q000639:trends; D011994:Recombinant Proteins / Q000494:pharmacology; D012065:Relaxin / Q000494:pharmacology*; D013318:Stroke Volume; D013777:Tetrazoles / Q000494:pharmacology*; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents; D004338:Drug Combinations; D011994:Recombinant Proteins; D013777:Tetrazoles; C577649:serelaxin protein, human; D000068756:Valsartan; D012065:Relaxin; C549068:sacubitril and valsartan sodium hydrate drug combination
keywords: Heart failure; LCZ696; Pharmacological therapy; clinical trials; serelaxin